A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.

Percent Change in eGFR Over Time Up through day 252/visit 9, the placebo arm showed a trend of declining eGFR including separation with nonoverlapping SE bars at day 140/visit 7 ( Figure 2 b) compared with either of the fresolimumab-treated arms, but P values were not statistically significant.

also in 53,322 other papers

There was a nonsignificant trend toward greater estimated glomerular filtration rate decline in the placebo group compared to either of the fresolimumab-treated arms up to day 252.

also in 5,406 other papers